• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Car T Cell Therapy Market

    ID: MRFR/Pharma/48107-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    UK CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), and By End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Car T Cell Therapy Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    UK Car T Cell Therapy Market Summary

    The United Kingdom CAR T Cell Therapy market is projected to experience substantial growth over the next decade.

    Key Market Trends & Highlights

    UK CAR T Cell Therapy Key Trends and Highlights

    • The market valuation is expected to rise from 415.8 USD Million in 2024 to 2075 USD Million by 2035.
    • A compound annual growth rate (CAGR) of 15.74 percent is anticipated from 2025 to 2035.
    • The increasing prevalence of hematological malignancies is likely to drive market expansion.
    • Growing adoption of CAR T Cell Therapy due to advancements in treatment efficacy is a major market driver.

    Market Size & Forecast

    2024 Market Size 415.8 (USD Million)
    2035 Market Size 2075 (USD Million)
    CAGR (2025-2035) 15.74%

    Major Players

    Bristol-Myers Squibb, Novartis, Celgene, Merck, Kite Pharma, Zymeworks, Gilead Sciences, Adaptimmune, Sangamo Therapeutics, Tessa Therapeutics, Bluebird Bio, Pfizer, Amgen, Janssen Pharmaceuticals, Humanigen

    UK Car T Cell Therapy Market Trends

    Due to a number of causes, the UK CAR T cell therapy market is expanding significantly. The increased incidence of blood malignancies like leukemia and lymphoma, which raises demand for cutting-edge treatment alternatives, is one major market driver.

    Acknowledging CAR T Cell therapy as an essential part of personalized medicine, the National Health Service (NHS) has been making significant investments in cutting-edge treatments.

    Furthermore, improvements in gene editing technologies like CRISPR are making it possible to create CAR T formulations that are safer and more effective, which is accelerating development and accessibility in the UK healthcare system.

    There are chances to increase patient access to CAR-T treatments, particularly by working with the NHS and pharmaceutical companies to support clinical trials involving cutting-edge treatment models.

    Furthermore, there is a chance to raise knowledge and educate people about CAR T therapy, especially patients and medical professionals. Treatment adoption can be enhanced by ongoing training and more thorough information sharing.

    An integrated strategy to CAR T therapy, in which interdisciplinary teams collaborate to maximize patient results, has become more popular in the UK in recent years. Additionally, there has been a noticeable emphasis on patient-centric strategies, which guarantee that treatment programs are customized to meet the needs of each patient.

    In order to improve the efficiency of the supply chain and lower treatment costs, the UK government and health authorities are also supporting the development of in-house manufacturing capabilities for CAR T cells. Consequently, these developments are not only changing the face of CAR T cell therapy in the UK but also strengthening the healthcare system to accommodate cutting-edge cancer therapies.

    UK CAR T

    UK Car T Cell Therapy Market Drivers

    Market Segment Insights

    CAR T

    The UK CAR T Cell Therapy Market demonstrates significant promise in the Therapeutic Area, with a concentration on Oncology, Autoimmune Diseases, and Infectious Diseases shaping its landscape. Oncology stands out as a prominent area fueled by the effective targeting of hematologic malignancies, such as various forms of blood cancer.

    The ongoing prevalence of cancer in the UK underscores the necessity for effective treatment alternatives, thereby driving research and innovation in CAR T cell therapies. Advances in genetic engineering and personalized medicine continue to elevate the importance of CAR T therapies within Oncology, making it a priority for investment and Research and Development.

    Autoimmune Diseases represent another critical segment within the UK CAR T Cell Therapy Market. As these diseases often involve the immune system attacking the body’s own tissues, the potential for CAR T therapies to reprogram immune responses opens new doors for effective treatments.

    The growing incidence of autoimmune conditions correlates with an increase in demand for innovative therapeutic options, providing opportunities for CAR T applications beyond oncology. This potential to mitigate conditions traditionally challenging to treat highlights the evolving role of CAR T cell therapies in addressing unmet medical needs.

    CAR T

    The Cell Source segment of the UK CAR T Cell Therapy Market is critical in shaping the landscape of cancer treatment. Autologous therapies, which utilize a patient's own cells, provide personalized treatment options, highlighting their effectiveness and reducing the risk of rejection.

    This approach has gained traction due to its relatively established safety profile. Conversely, Allogeneic therapies derived from donors are emerging as significant contenders, offering the potential for off-the-shelf solutions that could increase accessibility and reduce manufacturing time.

    Meanwhile, Gene-Edited therapies, which enhance the genetic modification of T cells, represent a cutting-edge area that promises to improve efficacy and target a wider range of malignancies. Collectively, these sources reflect ongoing Research and Development efforts within the UK, underpinned by supportive regulatory frameworks and heightened investment driven by a growing prevalence of cancers.

    Overall, the Cell Source segment not only embodies innovative strategies but also signifies the industry's commitment to advancing CAR T Cell Therapy, ultimately aiming to meet the diverse needs of patients combating complex conditions.

    CAR T

    The UK CAR T Cell Therapy Market, particularly within the Indication segment, is characterized by a remarkable focus on conditions such as Acute Lymphoblastic Leukemia, non-Hodgkin lymphoma, and Multiple Myeloma. Acute Lymphoblastic Leukemia is significant due to its prevalence among children and young adults, making it a critical target for advanced therapies.

    Non-Hodgkin Lymphoma has seen an increased adoption of CAR T Cell therapies as these treatments offer promising outcomes for patients who have exhausted other options. Meanwhile, Multiple Myeloma presents an increasing challenge in oncology, and CAR T Cell therapies are at the forefront of efforts to provide innovative treatment solutions for patients.

    The rising incidence rates of these hematological malignancies, coupled with advancements in research and technology, are driving the growth of the UK CAR T Cell Therapy Market.

    As patient access improves and regulatory approvals expand, these indications are expected to dominate the market landscape, creating significant opportunities for healthcare providers and stakeholders involved in the UK CAR T Cell Therapy Market industry.

    CAR T

    The End-user segment of the UK CAR T Cell Therapy Market encompasses Hospitals, Research Institutes, and Cancer Treatment Centers, which collectively play a critical role in the therapy's administration and innovation. Hospitals are pivotal in delivering CAR T Cell Therapy to patients, providing advanced facilities and healthcare professionals trained in this cutting-edge treatment.

    Research Institutes contribute significantly by focusing on the development of new CAR T therapies, driving innovation through clinical trials and research initiatives, which are vital for enhancing treatment efficacy.

    Cancer Treatment Centers specialize in delivering comprehensive care for cancer patients, offering both CAR T Cell Therapy and support services aimed at patient recovery. The collaboration between these entities fosters an integrated approach, addressing both immediate patient needs and long-term advancements in CAR T technologies.

    As the UK government continues to prioritize cancer treatment innovations, this segment is expected to evolve significantly, reflecting trends in personalized medicine and enhanced treatment protocols. Overall, the importance of each entity in this segment underscores the collaborative nature required to maximize the potential of CAR T Cell Therapy in the UK healthcare landscape.

    Get more detailed insights about UK Car T Cell Therapy Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The UK CAR T Cell Therapy Market has emerged as a pivotal segment within the broader landscape of oncological advancements, driven by the increasing prevalence of blood malignancies and the growing understanding of immunotherapy's potential.

    This innovative field allows for the modification of a patient's own T cells to target and destroy cancer cells more effectively, representing a significant leap forward in treatment methodologies.

    The competitive dynamics of this market are shaped by several key players, each contributing to the evolution of CAR T cell therapy through robust research and development, strategic partnerships, and extensive clinical trials.

    The landscape is characterized by an increasing number of approvals and a focus on improving patient outcomes, highlighting the competitive nature of organizations vying for dominance in this specialized arena.

    Bristol-Myers Squibb has established a significant foothold in the UK CAR T Cell Therapy Market, particularly through its innovative therapeutic solutions targeting hematological malignancies. The company's commitment to advancing CAR T therapies is underscored by its robust pipeline and strong investments in research and development.

    Bristol-Myers Squibb's strategic collaborations with healthcare providers and academic institutions in the UK further enhance its position, enabling it to leverage local expertise and access to patient populations.

    The company's strengths lie in its comprehensive approach to therapy development, focusing on not only the efficacy of its treatments but also the safety profiles that are crucial for patient acceptance and regulatory approval.

    Novartis is equally prominent within the UK CAR T Cell Therapy Market, known for its pioneering development of CAR T therapies that have been transformative for patients with certain types of blood cancers.

    The company's flagship CAR T product has received significant attention and uptake, supported by a strong clinical data package demonstrating its effectiveness. Novartis showcases a diverse portfolio within the CAR T segment and invests heavily in expanding access to its therapies through innovative distribution and patient support programs.

    The company's strength within the market is bolstered by strategic mergers and acquisitions that have enriched its capabilities and product offerings. Furthermore, Novartis continuously seeks collaboration with local healthcare systems to ensure that its groundbreaking therapies reach those in need, reinforcing its commitment to healthcare advancements in the UK.

    Key Companies in the UK Car T Cell Therapy Market market include

    Industry Developments

    Recent developments in the UK CAR T Cell Therapy Market have showcased a growing demand for innovative oncology treatments. Companies such as Bristol-Myers Squibb and Novartis continue to lead in the development of advanced therapies, with ongoing Research and Development efforts significantly enhancing patient outcomes.

    In April 2023, Gilead Sciences announced a collaboration with Adaptimmune to bolster its CAR T Cell Therapy pipeline, marking a significant step towards integration of innovative approaches in treatment. Meanwhile, Merck remains focused on expanding their CAR T offerings, potentially impacting their market position.

    The market has seen considerable growth, demonstrating strong valuations that are driven by increasing incidences of hematologic malignancies and a high rate of clinical approvals for CAR T therapies, particularly from Kite Pharma and Celgene.

    Notably, in November 2022, Bluebird Bio gained positive feedback for its innovative therapies, reinforcing its presence in the UK market. Mergers and acquisitions have also shaped the landscape, with Tessa Therapeutics acquiring promising proprietary technologies to enhance its therapeutic portfolio.

    Overall, the UK CAR T Cell Therapy Market is at a pivotal point, poised for substantial advancements and patient-focused solutions in the coming years.

    UK CAR T

    Market Segmentation

    Outlook

    • Hospitals
    • Research Institutes
    • Cancer Treatment Centers

    CAR T Cell Therapy Market End-user Outlook

    • Hospitals
    • Research Institutes
    • Cancer Treatment Centers

    CAR T Cell Therapy Market Indication Outlook

    • Acute Lymphoblastic Leukemia
    • Non-Hodgkin Lymphoma
    • Multiple Myeloma

    CAR T Cell Therapy Market Cell Source Outlook

    • Autologous
    • Allogeneic
    • Gene-Edited

    CAR T Cell Therapy Market Therapeutic Area Outlook

    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 360.0(USD Million)
    MARKET SIZE 2024 415.8(USD Million)
    MARKET SIZE 2035 2075.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 15.736% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Bristol Myers Squibb, Novartis, Celgene, Merck, Kite Pharma, Zymeworks, Gilead Sciences, Adaptimmune, Sangamo Therapeutics, Tessa Therapeutics, Bluebird Bio, Pfizer, Amgen, Janssen Pharmaceuticals, Humanigen
    SEGMENTS COVERED Therapeutic Area, Cell Source, Indication, End User
    KEY MARKET OPPORTUNITIES Growing demand for personalized medicine, Expansion of treatment options for cancers, Emerging partnerships with research institutions, Increased funding for innovative therapies, Enhanced regulatory support and approvals
    KEY MARKET DYNAMICS regulatory advancements, increasing cancer prevalence, high treatment costs, innovative research collaborations, growing patient awareness
    COUNTRIES COVERED UK

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the projected market value of the UK CAR T Cell Therapy Market in 2024?

    The UK CAR T Cell Therapy Market is expected to be valued at 415.8 million USD in 2024.

    What is the expected market value for the UK CAR T Cell Therapy Market by 2035?

    By 2035, the UK CAR T Cell Therapy Market is anticipated to reach a value of 2075.0 million USD.

    What is the anticipated compound annual growth rate (CAGR) for the UK CAR T Cell Therapy Market from 2025 to 2035?

    The market is expected to grow at a CAGR of 15.736% from 2025 to 2035.

    Which therapeutic area dominates the UK CAR T Cell Therapy Market?

    Oncology is the dominant therapeutic area, valued at 250.0 million USD in 2024.

    What will be the market size for oncology-related CAR T Cell therapies by 2035?

    The market size for oncology-related CAR T Cell therapies is projected to reach 1300.0 million USD by 2035.

    Who are the key players in the UK CAR T Cell Therapy Market?

    Major players include Bristol Myers Squibb, Novartis, Celgene, Merck, and Kite Pharma.

    What is the expected market size for CAR T Cell therapies targeting autoimmune diseases in 2024?

    The market for CAR T Cell therapies targeting autoimmune diseases is expected to be valued at 100.0 million USD in 2024.

    By 2035, what will be the market value for CAR T Cell therapies aimed at autoimmune diseases?

    By 2035, the market for CAR T Cell therapies for autoimmune diseases is anticipated to be valued at 400.0 million USD.

    What is the expected market size for CAR T Cell therapies for infectious diseases by 2035?

    The market for CAR T Cell therapies targeting infectious diseases is projected to reach 375.0 million USD by 2035.

    What is the expected value of the UK CAR T Cell Therapy Market for infectious diseases in 2024?

    The expected market value for CAR T Cell therapies for infectious diseases in 2024 is 65.8 million USD.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. UK CAR T Cell Therapy Market, BY Therapeutic Area (USD Million)
    45. Oncology
    46. Autoimmune Diseases
    47. Infectious Diseases
    48. UK CAR T Cell Therapy Market, BY Cell Source (USD Million)
    49. Autologous
    50. Allogeneic
    51. Gene-Edited
    52. UK CAR T Cell Therapy Market, BY Indication (USD Million)
    53. Acute Lymphoblastic Leukemia
    54. Non-Hodgkin Lymphoma
    55. Multiple Myeloma
    56. UK CAR T Cell Therapy Market, BY End User (USD Million)
    57. Hospitals
    58. Research Institutes
    59. Cancer Treatment Centers
    60. Competitive Landscape
    61. Overview
    62. Competitive Analysis
    63. Market share Analysis
    64. Major Growth Strategy in the CAR T Cell Therapy Market
    65. Competitive Benchmarking
    66. Leading Players in Terms of Number of Developments in the CAR T Cell Therapy Market
    67. Key developments and growth strategies
    68. New Product Launch/Service Deployment
    69. Merger & Acquisitions
    70. Joint Ventures
    71. Major Players Financial Matrix
    72. Sales and Operating Income
    73. Major Players R&D Expenditure. 2023
    74. Company Profiles
    75. Bristol Myers Squibb
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Novartis
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. Celgene
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Merck
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Kite Pharma
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. Zymeworks
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. Gilead Sciences
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Adaptimmune
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. Sangamo Therapeutics
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Tessa Therapeutics
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Bluebird Bio
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Pfizer
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Amgen
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Janssen Pharmaceuticals
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. Humanigen
    160. Financial Overview
    161. Products Offered
    162. Key Developments
    163. SWOT Analysis
    164. Key Strategies
    165. References
    166. Related Reports
    167. UK CAR T Cell Therapy Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2035 (USD Billions)
    168. UK CAR T Cell Therapy Market SIZE ESTIMATES & FORECAST, BY CELL SOURCE, 2019-2035 (USD Billions)
    169. UK CAR T Cell Therapy Market SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD Billions)
    170. UK CAR T Cell Therapy Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    171. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    172. ACQUISITION/PARTNERSHIP
    173. MARKET SYNOPSIS
    174. UK CAR T CELL THERAPY MARKET ANALYSIS BY THERAPEUTIC AREA
    175. UK CAR T CELL THERAPY MARKET ANALYSIS BY CELL SOURCE
    176. UK CAR T CELL THERAPY MARKET ANALYSIS BY INDICATION
    177. UK CAR T CELL THERAPY MARKET ANALYSIS BY END USER
    178. KEY BUYING CRITERIA OF CAR T CELL THERAPY MARKET
    179. RESEARCH PROCESS OF MRFR
    180. DRO ANALYSIS OF CAR T CELL THERAPY MARKET
    181. DRIVERS IMPACT ANALYSIS: CAR T CELL THERAPY MARKET
    182. RESTRAINTS IMPACT ANALYSIS: CAR T CELL THERAPY MARKET
    183. SUPPLY / VALUE CHAIN: CAR T CELL THERAPY MARKET
    184. CAR T CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2025 (% SHARE)
    185. CAR T CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019 TO 2035 (USD Billions)
    186. CAR T CELL THERAPY MARKET, BY CELL SOURCE, 2025 (% SHARE)
    187. CAR T CELL THERAPY MARKET, BY CELL SOURCE, 2019 TO 2035 (USD Billions)
    188. CAR T CELL THERAPY MARKET, BY INDICATION, 2025 (% SHARE)
    189. CAR T CELL THERAPY MARKET, BY INDICATION, 2019 TO 2035 (USD Billions)
    190. CAR T CELL THERAPY MARKET, BY END USER, 2025 (% SHARE)
    191. CAR T CELL THERAPY MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    192. BENCHMARKING OF MAJOR COMPETITORS

    UK CAR T Cell Therapy Market Segmentation

    • CAR T Cell Therapy Market By Therapeutic Area (USD Million, 2019-2035)

      • Oncology
      • Autoimmune Diseases
      • Infectious Diseases

    • CAR T Cell Therapy Market By Cell Source (USD Million, 2019-2035)

      • Autologous
      • Allogeneic
      • Gene-Edited

    • CAR T Cell Therapy Market By Indication (USD Million, 2019-2035)

      • Acute Lymphoblastic Leukemia
      • Non-Hodgkin Lymphoma
      • Multiple Myeloma

    • CAR T Cell Therapy Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Research Institutes
      • Cancer Treatment Centers
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027